Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

HLS Therapeutics Inc. (T:HLS)

Business Focus: Pharmaceuticals Wholesale

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for HLS within the last 6 months
See all filings within the past 6 months

Company News

Nov 14, 2023 16:12 ET
New REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Witho
Analysis Also Found Icosapent Ethyl Was Associated with a 41% Reduction in Total Events Compared with PlaceboSubgroup Almost Exclusively Comprised of Patients with Established Cardiovascular DiseaseFindings Continue to Reinforce the Scientific Data and Clinical Use of Vascepa® to Reduce Cardiovascular RiskResults Presented November 12, 2023, at the American Heart Association (AHA) Scientific Sessions 2023 and Simultaneously Published in the European Heart Journal OpenTORONTO, Nov. 14, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on
Read full article
Nov 09, 2023 05:30 ET
HLS Therapeutics Announces Q3 Fiscal 2023 Financial Results and Renewal of Normal Course Issuer Bid
TORONTO, Nov. 9, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three- and nine-month periods ended September 30, 2023. All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated.
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Nov 15, 202387,129-10,108
Oct 31, 202397,237-5,945
Oct 15, 2023103,1829,236
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

HLS Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on developing clinically differentiated pharmaceutical products in the specialty central nervous system (CNS) and cardiovascular (CV) markets. Its products include Vascepa, Trinomia, Clozaril, CSAN Pronto, PERSERIS and MyCare Psychiatry/MyCare Insite. Its lead product, Clozaril, is an atypical antipsychotic indicated in the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules reduce the risk of cardiovascular events, such as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or hospitalization for unstable angina in statin-treated patients with elevated triglycerides.

See business summary



Search (past week) for $HLS.CA

  • No tweets found